Holen Sie sich die Stockscreener-App
4.00
0.99%
-0.04
Handel nachbörslich:
4.00
Schlusskurs vom Vortag:
$4.04
Offen:
$4.14
24-Stunden-Volumen:
1.08M
Relative Volume:
1.10
Marktkapitalisierung:
$349.75M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.4162
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
+2.83%
1M Leistung:
+9.89%
6M Leistung:
+140.96%
1J Leistung:
-79.05%
1-Tages-Spanne:
$3.98
$4.24
1-Wochen-Bereich:
$3.74
$4.24
52-Wochen-Spanne:
$1.35
$24.43
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.00 | 353.24M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Fortgesetzt | Stifel | Buy |
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Why X4 Pharmaceuticals Inc. stock remains resilientQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - Business Wire
Why X4 Pharmaceuticals Inc. (48Q0) stock fits value portfoliosJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Layoff Tracker: Tessera Trimming 90 Employees as Part of Pipeline Prioritization - BioSpace
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - ulpravda.ru
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Finviz
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon - simplywall.st
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
IndMoney and Federal Bank Savings AccountBull Market Opportunities & Subscribe for Free Weekly Winners - Bollywood Helpline
Will X4 Pharmaceuticals Inc. (48Q0) stock boost dividends further2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Will X4 Pharmaceuticals Inc. stock continue upward momentumEarnings Trend Report & Safe Entry Trade Signal Reports - Улправда
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Price Targets & Free Community Supported Trade Ideas - Улправда
Can X4 Pharmaceuticals Inc. stock sustain institutional interestMarket Performance Report & Risk Controlled Stock Pick Alerts - Улправда
Can X4 Pharmaceuticals Inc. stock sustain market leadership2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Day Trade: Can X4 Pharmaceuticals Inc. stock sustain market leadershipQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Institution Moves: Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketMarket Growth Report & Risk Managed Investment Strategies - DonanımHaber
Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketTrade Entry Report & Capital Efficiency Focused Strategies - DonanımHaber
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Merger Talk: Is X4 Pharmaceuticals Inc. stock supported by strong fundamentals2025 Market Trends & Reliable Price Action Trade Plans - Улправда
• Position Sizing: Never all in — always size by riskInflation Impact on Stocks & Explosive Capital Gains - Bollywood Helpline
InMed Pharmaceuticals (INM) reports senior VP employee option expiration - Stock Titan
Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR) - Defense World
Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn
Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):